Now, it’s worth noting Stock Advisor's total average return is 1,039% — a market-crushing outperformance compared to 182% for ...

Results from the POLARGO trial “reinforce the benefit of adding polatuzumab to chemoimmunotherapy,” said Matthew Matasar, MD.

Also Read: UK’s Health Agency Endorses Pfizer’s Blood Cancer Combo Therapy As First For ... amounting to 8.8 billion yen.

We expect Amgen AMGN to beat expectations when it reports second-quarter 2025 results on Aug. 5 after market close. In the ...

The antibody discovery market is expanding, driven by the increasing incidence of chronic conditions such as cancer, diabetes, and cardiovascular and ...

The global biosimilars market is driven by less expensive alternatives made possible by the major biologics' patents expiring. The demand for reasonably ...

The global drug discovery platforms market size is calculated at USD 211.26 million in 2025 and is expected to reach around ...

AbbVie's trading session ended on a bearish note, with shares dipping to $187.64, nearly $4 below the day's high. The stock ...